Island Pharmaceuticals Ltd (AU:ILA)
ASX:ILA
ILA Stock Chart & Stats
AU$0.44
<AU$0.01(1.74%)
At close: 4:00 PM EST
AU$0.44
<AU$0.01(1.74%)
Day’s Range― - ―
52-Week RangeAU$0.12 - AU$0.63
Previous CloseN/A
Volume208.69K
Average Volume (3M)781.24K
Market Cap
AU$110.84M
Enterprise ValueAU$86.91M
Total Cash (Recent Filing)AU$6.87M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta-0.69
Next Earnings
Aug 20, 2026EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding295,581,700
10 Day Avg. Volume388,484
30 Day Avg. Volume781,243
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)3.39
Price to Sales (P/S)204.10
P/FCF Ratio-8.77
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthZero reported debt and a materially larger equity base provide a durable solvency buffer and financial flexibility. This reduces refinancing risk, supports continued R&D spending and gives management optionality for partnerships or licensing, aiding strategic execution over months.
Focused R&D PipelineA clear, concentrated focus on antiviral drug development creates a defined scientific and commercial niche. Structural demand for antivirals and specialized expertise can produce high-value, defensible assets if clinical progress continues, improving long-term upside versus unfocused early-stage peers.
Improving Cash Burn TrendA modest reduction in cash burn versus the prior year signals improving cost discipline and operational efficiency. Lower outflows extend runway, reduce near-term financing urgency, and help management sustain clinical programs or seek strategic partnerships across the next several months.
Bears Say
Negative Cash Flow / BurnPersistent negative operating and free cash flow reflects ongoing funding needs to advance clinical programs. This creates continuous dilution or debt risk, constrains the pace of development, and forces reliance on external financing, which can delay programs and dilute shareholders.
Weak Revenue & ProfitabilityA ~70% revenue decline and large net loss show fragile commercial traction and structural profitability problems. Without sustained revenue recovery or milestone-driven funding, the company cannot self-fund R&D and will face pressure to slow programs or seek dilutive capital.
Negative Returns & Dilution RiskOngoing negative returns on equity indicate shareholder capital is being consumed by operating deficits. Over the medium term this heightens the probability of equity raises, increasing dilution, eroding investor value, and limiting the company’s ability to pursue optional strategic opportunities.
Island Pharmaceuticals Ltd News
ILA FAQ
What was Island Pharmaceuticals Ltd’s price range in the past 12 months?
Island Pharmaceuticals Ltd lowest share price was AU$0.12 and its highest was AU$0.63 in the past 12 months.
What is Island Pharmaceuticals Ltd’s market cap?
Island Pharmaceuticals Ltd’s market cap is AU$110.84M.
When is Island Pharmaceuticals Ltd’s upcoming earnings report date?
Island Pharmaceuticals Ltd’s upcoming earnings report date is Aug 20, 2026 which is in 136 days.
How were Island Pharmaceuticals Ltd’s earnings last quarter?
Island Pharmaceuticals Ltd released its earnings results on Feb 19, 2026. The company reported -AU$0.019 earnings per share for the quarter, missing the consensus estimate of -AU$0.005 by -AU$0.014.
Is Island Pharmaceuticals Ltd overvalued?
According to Wall Street analysts Island Pharmaceuticals Ltd’s price is currently Overvalued.
Does Island Pharmaceuticals Ltd pay dividends?
Island Pharmaceuticals Ltd does not currently pay dividends.
What is Island Pharmaceuticals Ltd’s EPS estimate?
Island Pharmaceuticals Ltd’s EPS estimate is -0.01.
How many shares outstanding does Island Pharmaceuticals Ltd have?
Island Pharmaceuticals Ltd has 295,581,700 shares outstanding.
What happened to Island Pharmaceuticals Ltd’s price movement after its last earnings report?
Island Pharmaceuticals Ltd reported an EPS of -AU$0.019 in its last earnings report, missing expectations of -AU$0.005. Following the earnings report the stock price went up 1.351%.
Which hedge fund is a major shareholder of Island Pharmaceuticals Ltd?
Currently, no hedge funds are holding shares in AU:ILA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Island Pharmaceuticals Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:ILA Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth AU$76.0K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
100.00%
12-Months-Change
Fundamentals
Return on Equity
-100.58%
Trailing 12-Months
Asset Growth
86.01%
Trailing 12-Months
Company Description
Island Pharmaceuticals Ltd
Island Pharmaceuticals Limited, a drug research and repurposing company, focuses on the development of preventative or therapeutic drugs for viral infections. Its lead product candidate is ISLA-101, a drug for the prevention and treatment of dengue fever and other mosquito borne diseases. The company has a research collaboration agreement with Monash University to screen known molecules against host targets; research and development collaboration with Griffith University to screen for active anti-viral molecules in a rational repurposing strategy; and research collaboration agreement with Compounds Australia, a drug library containing approximately four and a half thousand molecules that could be searched for drug re-purposing and pipeline development. It also has a cooperative research and development agreement with the U.S. Army in preparation for its Phase II clinical study for ISLA-101; supply agreement with Catalent for manufacture of Fenretinide softgels for dengue fever trial participants; and right to reference National Cancer Institute IND for Isla101. The company was founded in 2017 and is based in Camberwell, Australia.
Technical Analysis
Cynata Therapeutics Limited
―
Prescient Therapeutics Limited
―
Starpharma Holdings Limited
―
AnteoTech Ltd
―
Neuroscientific Biopharmaceuticals Ltd.
―
Options Prices
Currently, No data available
---